BACKGROUND:Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plusLC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline. RESULTS: Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end. CONCLUSION: The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels.
RCT Entities:
BACKGROUND: Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline. RESULTS: Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end. CONCLUSION: The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels.
Authors: Sharon M Moe; Miriam P Zidehsarai; Mary A Chambers; Lisa A Jackman; J Scott Radcliffe; Laurie L Trevino; Susan E Donahue; John R Asplin Journal: Clin J Am Soc Nephrol Date: 2010-12-23 Impact factor: 8.237
Authors: Sarah Seiler; Birgit Reichart; Daniel Roth; Eric Seibert; Danilo Fliser; Gunnar H Heine Journal: Nephrol Dial Transplant Date: 2010-06-03 Impact factor: 5.992
Authors: Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein Journal: J Bone Miner Res Date: 2006-08 Impact factor: 6.741
Authors: Rodrigo B Oliveira; Ana L E Cancela; Fabiana G Graciolli; Luciene M Dos Reis; Sérgio A Draibe; Lilian Cuppari; Aluizio B Carvalho; Vanda Jorgetti; Maria E Canziani; Rosa M A Moysés Journal: Clin J Am Soc Nephrol Date: 2009-11-12 Impact factor: 8.237
Authors: Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn Journal: Clin J Am Soc Nephrol Date: 2008-12-03 Impact factor: 8.237
Authors: Pablo Florenzano; Macarena Jimenez; Carlos R Ferreira; Galina Nesterova; Mary Scott Roberts; Sri Harsha Tella; Luis Fernandez de Castro; Rachel I Gafni; Myles Wolf; Harald Jüppner; Barbara Gales; Katherine Wesseling-Perry; Daniela Markovich; William A Gahl; Isidro B Salusky; Michael T Collins Journal: J Am Soc Nephrol Date: 2020-07-06 Impact factor: 10.121
Authors: Tamara Isakova; Xuan Cai; Jungwha Lee; Dawei Xie; Xue Wang; Rupal Mehta; Norrina B Allen; Julia J Scialla; Michael J Pencina; Amanda H Anderson; John Talierco; Jing Chen; Michael J Fischer; Susan P Steigerwalt; Mary B Leonard; Chi-Yuan Hsu; Ian H de Boer; John W Kusek; Harold I Feldman; Myles Wolf Journal: J Am Soc Nephrol Date: 2017-11-22 Impact factor: 10.121
Authors: Aaltje Y Adema; Maarten A de Jong; Martin H de Borst; Pieter M Ter Wee; Marc G Vervloet Journal: Nephron Date: 2016-07-22 Impact factor: 2.847
Authors: Yifu Fang; Charles Ginsberg; Michael Seifert; Olga Agapova; Toshifumi Sugatani; Thomas C Register; Barry I Freedman; Marie-Claude Monier-Faugere; Hartmut Malluche; Keith A Hruska Journal: J Am Soc Nephrol Date: 2014-02-27 Impact factor: 10.121